The trace element chromium, and particularly chromium picolinate, will likely find a greater role in the management of insulin resistance and Type 2 diabetes (T2D) in the coming years, as clinical evidence accumulates to support its antiglycemic, insulin-sensitizing effects. Chromium researchers from across the globe recently gathered to share their findings at a summit sponsored by the Council for the Advancement of Diabetes Research and Education (CADRE).